Literature DB >> 31203474

Probabilistic chemotherapy in knee and hip replacement infection: the place of linezolid.

Luc Deroche1, Chloé Plouzeau1, Pascale Bémer2, Didier Tandé3, Anne Sophie Valentin4, Anne Jolivet-Gougeon5, Carole Lemarié6, Laurent Bret7, Marie Kempf6, Geneviève Héry-Arnaud3, Stéphane Corvec2, Christophe Burucoa1, Cédric Arvieux8, Louis Bernard9.   

Abstract

Prosthetic joint infection (PJI) can occur with a wide range of microorganisms and clinical features. After replacement surgery of prosthetic joint, prescription of probabilistic broad-spectrum antimicrobial therapy is usual, while awaiting microbial culture results. The aim of our study was to describe the antibiotic susceptibility of microorganisms isolated from hip and knee PJI. The data were collected to determine the best alternative to the usual combination of piperacillin-tazobactam (TZP) or cefotaxime (CTX) and vancomycin (VAN). Based on a French prospective, multicenter study, we analyzed microbiological susceptibility to antibiotics of 183 strains isolated from patients with confirmed hip or knee PJI. In vitro susceptibility was evaluated: TZP+VAN, TZP+linezolid (LZD), CTX+VAN, and CTX+LZD. We also analyzed resistance to different antibiotics commonly used as oral alternatives. Among the 183 patients with PJI, 62 (34%) had a total knee prosthesis, and 121 (66%) a hip prosthesis. The main identified bacteria were Staphylococcus aureus (32.2% of isolates), coagulase-negative staphylococci (27.3%), Enterobacteriaceae (14.2%), and Streptococcus (13.7%). Infections were polymicrobial for 28 (15.3%) patients. All combinations were highly effective: CTX+VAN, CTX+LZD, TZP+VAN, and TZP+LZD (93.4%, 94%, 98.4%, and 98.9% of all cases respectively). Use of LZD instead of VAN in combination with a broad-spectrum beta-lactam covers almost all of the bacteria isolated in PJI. This association should be considered in probabilistic chemotherapy, as it is particularly easy to use (oral administration and no vancomycin monitoring).

Entities:  

Keywords:  Probabilistic antibiotics; Prosthetic joint infection

Mesh:

Substances:

Year:  2019        PMID: 31203474     DOI: 10.1007/s10096-019-03594-z

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  5 in total

Review 1.  Antibiotic Therapy for Prosthetic Joint Infections: An Overview.

Authors:  Benjamin Le Vavasseur; Valérie Zeller
Journal:  Antibiotics (Basel)       Date:  2022-04-05

Review 2.  New developments and future challenges in prevention, diagnosis, and treatment of prosthetic joint infection.

Authors:  Benjamin F Ricciardi; Gowrishankar Muthukrishnan; Elysia A Masters; Nathan Kaplan; John L Daiss; Edward M Schwarz
Journal:  J Orthop Res       Date:  2020-01-31       Impact factor: 3.494

3.  Low prevalence of tissue detection of cefepime and daptomycin used as empirical treatment during revision for periprosthetic joint infections: results of a prospective multicenter study.

Authors:  O Robineau; E Talagrand-Reboulh; B Brunschweiler; F Jehl; E Beltrand; F Rousseau; N Blondiaux; A Grillon; C Joseph; P Lambotte; P Boyer; Eric Senneville
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2021-05-20       Impact factor: 3.267

4.  The Right Time to Safely Re-Evaluate Empirical Antimicrobial Treatment of Hip or Knee Prosthetic Joint Infections.

Authors:  Luc Deroche; Pascale Bémer; Anne-Sophie Valentin; Anne Jolivet-Gougeon; Didier Tandé; Geneviève Héry-Arnaud; Carole Lemarié; Marie Kempf; Laurent Bret; Christophe Burucoa; Stéphane Corvec; Chloé Plouzeau
Journal:  J Clin Med       Date:  2019-12-02       Impact factor: 4.241

5.  Thematic research clusters in very old populations (≥ 80 years): a bibliometric approach.

Authors:  Gregorio Gonzalez-Alcaide; Sergio Palacios-Fernandez; Jose-Manuel Ramos-Rincon
Journal:  BMC Geriatr       Date:  2021-04-21       Impact factor: 3.921

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.